EG 427 is a French biotechnology company that specializes in pinpoint gene therapy, delivering therapeutic genes directly to targeted cells to treat genetic disorders. This precise approach aims to correct faulty genes, improving patient outcomes while minimizing off-target effects.
Funding
$20.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many chronic diseases, especially those with localized impact, lack therapies that can safely and effectively target the affected cells while minimizing systemic side effects. Traditional gene therapy approaches may not offer the precision needed to address these localized conditions effectively.
Solution
EG 427 is developing pinpoint DNA medicines for chronic diseases by leveraging non-replicative Herpes Simplex Virus 1 (nrHSV-1) vectors as a gene therapy platform. This platform enables the expression of large genes under the control of sophisticated regulatory elements, offering a safe and redosable approach. The company engineers vectors with specific promoters to achieve targeted effects in specific neuronal subsets of the sensory or autonomic nervous systems. Their technology aims to establish lifelong latency in peripheral neurons, ensuring safe, highly specific, and durable expression of disease-modifying transgenes.
Target Audience
The primary target audience includes patients with severe localized chronic diseases, particularly those affecting the peripheral nervous system, such as underserved bladder disorders.
Features
- Utilizes non-replicative Herpes Simplex Virus 1 (nrHSV-1) vectors for targeted gene delivery.
- Enables expression of large genes with sophisticated regulatory control.
- Focuses on achieving lifelong latency in peripheral neurons for durable transgene expression.
- Developing a pipeline of vectors targeting different indications, with an initial focus on peripheral nervous system disorders.